Kyverna’s miv-cel shows sustained benefit in Phase 1 progressive multiple sclerosis trial

• Kyverna Therapeutics announced updated Phase 1 results for miv-cel in progressive multiple sclerosis for presentation today at MS Toronto 2026.
• In the six-patient study, all five evaluable patients had stable or improved disability, with four sustaining benefit through one year.
• Four patients maintained improvement beyond one year without chronic immunotherapies; the first treated patient sustained clinical benefit beyond two years.
• Treatment was well tolerated, with no high-grade CRS or reported cases of ICANS or IEC-HS.
• Miv-cel received RMAT designation for non-active secondary progressive multiple sclerosis; a development strategy update is expected by early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231030PRIMZONEFULLFEED9851960) on October 23, 2026, and is solely responsible for the information contained therein.